eClinical Solutions Market by Product (CDMS, EDC, CTMS, eCOA, RTSM, eTMF, Safety), Deployment (On premise, Cloud), Application (Collection, Operations, Analytics), Trial Phase, End user (Pharma, Biotech, Med Devices), & Region - Global Forecast to 2029
The global eClinical solutions market is projected to reach USD 22.1 billion by 2029 from USD 11.6 billion in 2024, at a high CAGR of 13.7% during the forecast period. Growth Drivers include the rising operational costs and regulatory obligations for all clinical research studies, adoption of innovative software solutions for clinical research, favourable government funding received for clinical trials, rising need for better standardization and quality of clinical data, and growing R&D expenditure on drug development by pharmaceutical-biotech companies. There are some inhibitive factors, such as the high rate of implementation of eClinical solutions, scarcity of skilled professionals to implement and manage these solutions, and inadequate awareness about the benefits of eClinical solutions among researchers.
“In 2023, data collection segment constituted the largest segment in the eClinical solutions market, by application.”
In 2023, the data collection segment accounted for the biggest proportion of the eClinical solutions market, by application. This growth is primarily driven by solutions such as electronic data capture (EDC) systems, which streamline the process by reducing manual errors, speeding up data entry, and allowing for real-time access to data; the growing need to comply with stringent regulatory standards and support remote and decentralised trials; and its growing importance in clinical trial success, as it ensures the integrity and quality of the data being gathered.
“In 2023, the pharmaceutical & biopharmaceutical companies held the largest market share among end users.”
In 2023, pharmaceutical and biopharmaceutical firms accounted for the highest proportion of the eClinical solutions market by end user. This dominance stems primarily from the enormous number of corporations' investments in clinical trials and drug development. These companies run numerous clinical studies to get their innovative medications and cures to market, necessitating significantly improved eClinical systems to manage the complicated processes involved. Furthermore, these organizations have significant financial resources to invest in eClinical solutions, allowing them to adopt cutting-edge technology and developments, hence, fueling the industry.
“In 2023, North America was the largest regional market for eClinical solutions market.”
In 2023, North America had the highest share of the eClinical Solutions market. This segment's highest share is attributed to its advanced healthcare infrastructure, major R&D investments, and strict regulatory environment. Big Pharma companies like Pfizer and Johnson & Johnson that conduct clinical trials on a large scale are the ones responsible for the high demand of these solutions. The region's high digital literacy and technological innovation given by companies such as Medidata Solutions propel the widespread use of eClinical solutions. The availability of regulatory frameworks, such as the FDA's 21 CFR Part 11, ensures compliance while driving up demand for sophisticated data management and clinical trial solutions.
The break-down of primary participants is as mentioned below:
The key players functioning in the EClinical solutions market include Medidata (A Dassault Syst?mes Company) (France), Veeva Systems (US), IQVIA Inc. (US), ICON plc (Ireland), Oracle (US), Signant Health (US), Clario (US), and eClinical Solutions (US).
Research Coverage:
The report analyses the eClinical solutions market. It aims to estimate the market size and future growth potential of various market segments based on product, deployment model, application, clinical trial phase, end-user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
“In 2023, data collection segment constituted the largest segment in the eClinical solutions market, by application.”
In 2023, the data collection segment accounted for the biggest proportion of the eClinical solutions market, by application. This growth is primarily driven by solutions such as electronic data capture (EDC) systems, which streamline the process by reducing manual errors, speeding up data entry, and allowing for real-time access to data; the growing need to comply with stringent regulatory standards and support remote and decentralised trials; and its growing importance in clinical trial success, as it ensures the integrity and quality of the data being gathered.
“In 2023, the pharmaceutical & biopharmaceutical companies held the largest market share among end users.”
In 2023, pharmaceutical and biopharmaceutical firms accounted for the highest proportion of the eClinical solutions market by end user. This dominance stems primarily from the enormous number of corporations' investments in clinical trials and drug development. These companies run numerous clinical studies to get their innovative medications and cures to market, necessitating significantly improved eClinical systems to manage the complicated processes involved. Furthermore, these organizations have significant financial resources to invest in eClinical solutions, allowing them to adopt cutting-edge technology and developments, hence, fueling the industry.
“In 2023, North America was the largest regional market for eClinical solutions market.”
In 2023, North America had the highest share of the eClinical Solutions market. This segment's highest share is attributed to its advanced healthcare infrastructure, major R&D investments, and strict regulatory environment. Big Pharma companies like Pfizer and Johnson & Johnson that conduct clinical trials on a large scale are the ones responsible for the high demand of these solutions. The region's high digital literacy and technological innovation given by companies such as Medidata Solutions propel the widespread use of eClinical solutions. The availability of regulatory frameworks, such as the FDA's 21 CFR Part 11, ensures compliance while driving up demand for sophisticated data management and clinical trial solutions.
The break-down of primary participants is as mentioned below:
- By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
- By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%
The key players functioning in the EClinical solutions market include Medidata (A Dassault Syst?mes Company) (France), Veeva Systems (US), IQVIA Inc. (US), ICON plc (Ireland), Oracle (US), Signant Health (US), Clario (US), and eClinical Solutions (US).
Research Coverage:
The report analyses the eClinical solutions market. It aims to estimate the market size and future growth potential of various market segments based on product, deployment model, application, clinical trial phase, end-user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
- Analysis of key drivers: (increasing operational costs and regulatory requirements associated with clinical research studies), restraints (high implementation costs associated with eClinical solutions), opportunities (growing number of clinical trials in developing nations), and challenges (concerns pertaining to patient privacy) influencing the growth of the eClinical solutions market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the eClinical solutions market.
- Market Development: Comprehensive information on the lucrative emerging markets, products, deployment models, applications, clinical trial phase, end-users, and regions.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the eClinical solutions market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the eClinical solutions market like Medidata (A Dassault Syst?mes Company) (France), Veeva Systems (US), IQVIA Inc. (US), ICON plc (Ireland), Oracle (US), Signant Health (US), Clario (US), and eClinical Solutions (US).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 IMPACT OF AI/GEN AI
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ECLINICAL SOLUTIONS MARKET OVERVIEW
4.2 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
AND COUNTRY, 2024
4.3 ECLINICAL SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 ECLINICAL SOLUTIONS MARKET REGIONAL MIX
4.5 ECLINICAL SOLUTIONS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing focus on cost-effective processes
5.2.1.2 Favorable government support and funding
5.2.1.3 Need for data standardization
5.2.1.4 Increasing R&D expenditure on drug development
5.2.2 RESTRAINTS
5.2.2.1 High implementation costs
5.2.2.2 Lack of skilled professionals
5.2.2.3 Limited awareness among researchers
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing number of clinical trials
5.2.3.2 Outsourcing of clinical trials
5.2.3.3 Gradual shift toward real-time data analysis
5.2.4 CHALLENGES
5.2.4.1 Limited adoption in developing and underdeveloped countries
5.2.4.2 Software reliability issues
5.2.4.3 Patient privacy concerns
5.3 ECOSYSTEM ANALYSIS
5.3.1 HEALTHCARE PROVIDERS
5.3.2 CLOUD PROVIDERS
5.3.3 GOVERNMENT AGENCIES AND REGULATORY BODIES
5.3.4 ECLINICAL SOLUTION COMPANIES
5.4 CASE STUDY ANALYSIS
5.4.1 ENHANCED PATIENT RECORDS USING MEDIDATA ECOA APP
5.4.2 IMPROVED ALZHEIMER’S TREATMENT WITH LEQEMB THERAPY
5.4.3 EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
5.5 VALUE CHAIN ANALYSIS
5.6 PORTER'S FIVE FORCES ANALYSIS
5.6.1 BARGAINING POWER OF SUPPLIERS
5.6.2 BARGAINING POWER OF BUYERS
5.6.3 THREAT OF SUBSTITUTES
5.6.4 THREAT OF NEW ENTRANTS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY LANDSCAPE
5.7.1 REGULATORY ANALYSIS
5.7.1.1 North America
5.7.1.2 Europe
5.7.1.3 Asia Pacific
5.7.1.4 Latin America
5.7.1.5 Middle East & Africa
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR ECLINICAL SOLUTIONS
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 AI-enabled and integrated platforms
5.9.1.2 Clinical data integration
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Cloud computing
5.9.2.2 Analytical tools
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Electronic health records
5.9.3.2 Real-world data
5.9.3.3 Bioinformatics
5.10 INDUSTRY TRENDS
5.10.1 DECENTRALIZED CLINICAL TRIALS
5.10.2 TELEMEDICINE
5.10.3 BIG DATA
5.11 PRICING ANALYSIS
5.11.1 INDICATIVE PRICING ANALYSIS, BY DEPLOYMENT MODEL
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION
5.12 KEY CONFERENCES AND EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 BUYING CRITERIA
5.14 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.15 END-USER ANALYSIS
5.15.1 UNMET NEEDS
5.15.2 END-USER EXPECTATIONS
5.16 INVESTMENT AND FUNDING SCENARIO
5.17 IMPACT OF AI/GEN AI ON ECLINICAL SOLUTIONS MARKET
5.17.1 KEY USE CASES
5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
5.17.2.1 Case study
5.17.2.2 Clinical trial management system market
5.17.2.3 Clinical trial market
5.17.2.4 Electronic clinical outcome assessment solution market
5.17.3 USER READINESS AND IMPACT ASSESSMENT
5.17.3.1 User readiness
5.17.3.1.1 Pharmaceutical and biopharmaceutical companies
5.17.3.1.2 Contract research organizations
5.17.3.2 Impact assessment
5.17.3.2.1 User A: Pharmaceutical & biopharmaceutical companies
5.17.3.2.1.1 Implementation
5.17.3.2.1.2 Impact
5.17.3.2.2 User B: Academic research institutes
5.17.3.2.2.1 Implementation
5.17.3.2.2.2 Impact
6 ECLINICAL SOLUTIONS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SOLUTIONS
6.2.1 RISING NEED TO REDUCE TIME AND COSTS IN CLINICAL TRIALS TO ENCOURAGE GROWTH
6.3 CLINICAL TRIAL MANAGEMENT SOLUTIONS
6.3.1 RISING DEMAND FOR SITE & DATA COLLECTION SOLUTIONS TO FACILITATE GROWTH
6.4 CLINICAL ANALYTICS PLATFORMS
6.4.1 GROWING ADOPTION OF ELECTRONIC MEDICAL RECORDS TO BOOST MARKET
6.5 RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SOLUTIONS
6.5.1 GROWING TREND OF GLOBALIZATION TO FUEL MARKET
6.6 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS
6.6.1 INCREASING ADOPTION OF EDIARIES TO AID GROWTH
6.7 ELECTRONIC TRIAL MASTER FILE SOLUTIONS
6.7.1 IMPROVED INFORMATION SEARCH AND RETRIEVAL TO FUEL MARKET
6.8 ELECTRONIC CONSENT SOLUTIONS
6.8.1 GROWING INCLINATION TOWARD DIGITIZATION TO PROMOTE GROWTH
6.9 REGULATORY INFORMATION MANAGEMENT SOLUTIONS
6.9.1 ENHANCED REGULATORY SUBMISSION PROCESS TO AUGMENT GROWTH
6.10 CLINICAL DATA INTEGRATION PLATFORMS
6.10.1 GROWING VOLUME OF CLINICAL DATA AND IMPROVED CLOUD TECHNOLOGY TO PROPEL MARKET
6.11 SAFETY SOLUTIONS
6.11.1 GROWING ADOPTION OF ECLINICAL SOFTWARE TO SUPPORT MARKET GROWTH
6.12 OTHER SOLUTIONS
7 ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL
7.1 INTRODUCTION
7.2 WEB-HOSTED & CLOUD-BASED MODELS
7.2.1 GROWING DEMAND FOR CLOUD-BASED SOLUTIONS TO AUGMENT GROWTH
7.3 ON-PREMISE MODELS
7.3.1 MINIMIZED DATA BREACHES AND EXTERNAL ATTACK RISKS TO SUPPORT MARKET
8 ECLINICAL SOLUTIONS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DATA COLLECTION
8.2.1 IMPROVED TRIAL EFFICIENCY TO DRIVE MARKET
8.3 DOCUMENT MANAGEMENT & STORAGE
8.3.1 RISING INCLINATION TOWARD STREAMLINED DOCUMENT WORKFLOWS TO FUEL MARKET
8.4 SUPPLY MANAGEMENT
8.4.1 NEED TO ADDRESS COMPLEXITIES IN MANAGING CLINICAL TRIAL SUPPLIES TO BOOST MARKET
8.5 DATA ANALYTICS
8.5.1 INCREASING NEED FOR OPTIMIZED TRIAL DESIGNS TO AID GROWTH
8.6 CLINICAL TRIAL OPERATIONS
8.6.1 GROWING FOCUS ON ENHANCED DRUG DEVELOPMENT TO PROPEL MARKET
8.7 REGULATORY INFORMATION MANAGEMENT
8.7.1 EVOLVING GLOBAL REGULATORY STANDARDS TO STIMULATE GROWTH
8.8 OTHER APPLICATIONS
9 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
9.1 INTRODUCTION
9.2 PHASE I
9.2.1 INCREASING DEMAND FOR ACCURATE CLINICAL DATA MANAGEMENT TO ACCELERATE GROWTH
9.3 PHASE II
9.3.1 PUSH TOWARD FASTER DRUG DEVELOPMENT TO FACILITATE GROWTH
9.4 PHASE III
9.4.1 INVOLVEMENT OF LARGE PATIENT POPULATION TO ENCOURAGE SEGMENT GROWTH
9.5 PHASE IV
9.5.1 GROWING EMPHASIS ON SAFE DRUGS TO DRIVE MARKET
10 ECLINICAL SOLUTIONS MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
10.2.1 INCREASING R&D EXPENDITURE TO DRIVE MARKET
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.3.1 GROWING OUTSOURCING OF CLINICAL TRIALS TO FUEL MARKET
10.4 CONSULTING SERVICE COMPANIES
10.4.1 INCREASING COMPLEXITIES AND COSTS OF CLINICAL DATA MANAGEMENT TO PROPEL MARKET
10.5 MEDICAL DEVICE MANUFACTURERS
10.5.1 RISING DEVELOPMENT OF NEW MEDICAL DEVICES TO BOOST MARKET
10.6 HOSPITALS & HEALTHCARE PROVIDERS
10.6.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND ECLINICAL SOLUTION PROVIDERS TO STIMULATE MARKET
10.7 ACADEMIC & RESEARCH INSTITUTES
10.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO EXPEDITE GROWTH
10.8 GOVERNMENT ORGANIZATIONS
10.8.1 INCREASED ADOPTION BY HEALTH DEPARTMENTS AND REGULATORY BODIES TO SPEED UP GROWTH
10.9 OTHER END USERS
11 ECLINICAL SOLUTIONS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Rising government funding for pharmaceutical R&D to drive market
11.2.3 CANADA
11.2.3.1 Advanced facilities and shorter approval times for drug candidates to fuel market
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 High number of sponsored clinical trials to augment growth
11.3.3 UK
11.3.3.1 Increased investments by pharmaceutical companies to boost market
11.3.4 FRANCE
11.3.4.1 Booming generics market to aid growth
11.3.5 ITALY
11.3.5.1 Favorable drug approval scenario to support market growth
11.3.6 SPAIN
11.3.6.1 Robust network of research centers, universities, and hospitals to encourage growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Low manufacturing costs and huge demand for medicines to expedite growth
11.4.3 INDIA
11.4.3.1 Growing foreign direct investments to facilitate market growth
11.4.4 JAPAN
11.4.4.1 Drug discovery and development initiatives to promote growth
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Higher adoption of advanced digital technologies to stimulate growth
11.5.3 MEXICO
11.5.3.1 Government initiatives to enhance digital infrastructure of healthcare to propel market
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2 GCC COUNTRIES
11.6.2.1 Growing modernization initiatives in healthcare sector to support market growth
11.6.3 REST OF MIDDLE EAST & AFRICA
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.3 REVENUE ANALYSIS, 2019–2023
12.4 MARKET SHARE ANALYSIS, 2023
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
12.5.5.2 Product footprint
12.5.5.3 Application footprint
12.5.5.4 End-user footprint
12.5.5.5 Region footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 COMPANY EVALUATION AND FINANCIAL METRICS
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES AND ENHANCEMENTS
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 MEDIDATA (A DASSAULT SYST?MES COMPANY)
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches and enhancements
13.1.1.3.2 Deals
13.1.1.4 MnM view
13.1.1.4.1 Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 VEEVA SYSTEMS
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Product launches and enhancements
13.1.2.3.2 Deals
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 IQVIA INC.
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Deals
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 ICON PLC
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Product launches and enhancements
13.1.4.3.2 Deals
13.1.5 ORACLE
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Deals
13.1.6 SIGNANT HEALTH
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Product launches and enhancements
13.1.6.3.2 Deals
13.1.7 CLARIO
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Product launches and enhancements
13.1.7.3.2 Deals
13.1.7.3.3 Other developments
13.1.8 ECLINICAL SOLUTIONS
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product launches and enhancements
13.1.8.3.2 Deals
13.1.9 CLINION
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.9.3 Recent developments
13.1.9.3.1 Product launches and enhancements
13.1.9.3.2 Deals
13.1.10 MAXISIT
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.11 4G CLINICAL
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.11.3 Recent developments
13.1.11.3.1 Deals
13.1.12 FOUNTAYN
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.13 SAAMA
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3.1 Deals
13.1.14 MEDNET
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.14.3 Recent developments
13.1.14.3.1 Product launches and enhancements
13.1.14.3.2 Deals
13.1.15 ADVARRA
13.1.15.1 Business overview
13.1.15.2 Products offered
13.1.15.3 Recent developments
13.1.15.3.1 Product launches and enhancements
13.1.15.3.2 Deals
13.1.16 CAIDYA
13.1.16.1 Business overview
13.1.16.2 Products offered
13.1.16.3 Recent developments
13.1.16.3.1 Deals
13.1.16.3.2 Expansions
13.1.17 OPENCLINICA, LLC
13.1.17.1 Business overview
13.1.17.2 Products offered
13.1.17.3 Recent developments
13.1.17.3.1 Deals
13.1.18 EVIDENTIQ
13.1.18.1 Business overview
13.1.18.2 Products offered
13.1.18.3 Recent developments
13.1.18.3.1 Product launches and enhancements
13.1.18.3.2 Deals
13.2 OTHER PLAYERS
13.2.1 RESEARCH MANAGER
13.2.2 ANJU SOFTWARE INC.
13.2.3 MEDRIO
13.2.4 CASTOR
13.2.5 REALTIME SOFTWARE SOLUTIONS, LLC
13.2.6 YPRIME, LLC.
13.2.7 VIAL
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 IMPACT OF AI/GEN AI
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ECLINICAL SOLUTIONS MARKET OVERVIEW
4.2 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
AND COUNTRY, 2024
4.3 ECLINICAL SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 ECLINICAL SOLUTIONS MARKET REGIONAL MIX
4.5 ECLINICAL SOLUTIONS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing focus on cost-effective processes
5.2.1.2 Favorable government support and funding
5.2.1.3 Need for data standardization
5.2.1.4 Increasing R&D expenditure on drug development
5.2.2 RESTRAINTS
5.2.2.1 High implementation costs
5.2.2.2 Lack of skilled professionals
5.2.2.3 Limited awareness among researchers
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing number of clinical trials
5.2.3.2 Outsourcing of clinical trials
5.2.3.3 Gradual shift toward real-time data analysis
5.2.4 CHALLENGES
5.2.4.1 Limited adoption in developing and underdeveloped countries
5.2.4.2 Software reliability issues
5.2.4.3 Patient privacy concerns
5.3 ECOSYSTEM ANALYSIS
5.3.1 HEALTHCARE PROVIDERS
5.3.2 CLOUD PROVIDERS
5.3.3 GOVERNMENT AGENCIES AND REGULATORY BODIES
5.3.4 ECLINICAL SOLUTION COMPANIES
5.4 CASE STUDY ANALYSIS
5.4.1 ENHANCED PATIENT RECORDS USING MEDIDATA ECOA APP
5.4.2 IMPROVED ALZHEIMER’S TREATMENT WITH LEQEMB THERAPY
5.4.3 EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
5.5 VALUE CHAIN ANALYSIS
5.6 PORTER'S FIVE FORCES ANALYSIS
5.6.1 BARGAINING POWER OF SUPPLIERS
5.6.2 BARGAINING POWER OF BUYERS
5.6.3 THREAT OF SUBSTITUTES
5.6.4 THREAT OF NEW ENTRANTS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY LANDSCAPE
5.7.1 REGULATORY ANALYSIS
5.7.1.1 North America
5.7.1.2 Europe
5.7.1.3 Asia Pacific
5.7.1.4 Latin America
5.7.1.5 Middle East & Africa
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR ECLINICAL SOLUTIONS
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 AI-enabled and integrated platforms
5.9.1.2 Clinical data integration
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Cloud computing
5.9.2.2 Analytical tools
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Electronic health records
5.9.3.2 Real-world data
5.9.3.3 Bioinformatics
5.10 INDUSTRY TRENDS
5.10.1 DECENTRALIZED CLINICAL TRIALS
5.10.2 TELEMEDICINE
5.10.3 BIG DATA
5.11 PRICING ANALYSIS
5.11.1 INDICATIVE PRICING ANALYSIS, BY DEPLOYMENT MODEL
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION
5.12 KEY CONFERENCES AND EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 BUYING CRITERIA
5.14 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.15 END-USER ANALYSIS
5.15.1 UNMET NEEDS
5.15.2 END-USER EXPECTATIONS
5.16 INVESTMENT AND FUNDING SCENARIO
5.17 IMPACT OF AI/GEN AI ON ECLINICAL SOLUTIONS MARKET
5.17.1 KEY USE CASES
5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
5.17.2.1 Case study
5.17.2.2 Clinical trial management system market
5.17.2.3 Clinical trial market
5.17.2.4 Electronic clinical outcome assessment solution market
5.17.3 USER READINESS AND IMPACT ASSESSMENT
5.17.3.1 User readiness
5.17.3.1.1 Pharmaceutical and biopharmaceutical companies
5.17.3.1.2 Contract research organizations
5.17.3.2 Impact assessment
5.17.3.2.1 User A: Pharmaceutical & biopharmaceutical companies
5.17.3.2.1.1 Implementation
5.17.3.2.1.2 Impact
5.17.3.2.2 User B: Academic research institutes
5.17.3.2.2.1 Implementation
5.17.3.2.2.2 Impact
6 ECLINICAL SOLUTIONS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SOLUTIONS
6.2.1 RISING NEED TO REDUCE TIME AND COSTS IN CLINICAL TRIALS TO ENCOURAGE GROWTH
6.3 CLINICAL TRIAL MANAGEMENT SOLUTIONS
6.3.1 RISING DEMAND FOR SITE & DATA COLLECTION SOLUTIONS TO FACILITATE GROWTH
6.4 CLINICAL ANALYTICS PLATFORMS
6.4.1 GROWING ADOPTION OF ELECTRONIC MEDICAL RECORDS TO BOOST MARKET
6.5 RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SOLUTIONS
6.5.1 GROWING TREND OF GLOBALIZATION TO FUEL MARKET
6.6 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS
6.6.1 INCREASING ADOPTION OF EDIARIES TO AID GROWTH
6.7 ELECTRONIC TRIAL MASTER FILE SOLUTIONS
6.7.1 IMPROVED INFORMATION SEARCH AND RETRIEVAL TO FUEL MARKET
6.8 ELECTRONIC CONSENT SOLUTIONS
6.8.1 GROWING INCLINATION TOWARD DIGITIZATION TO PROMOTE GROWTH
6.9 REGULATORY INFORMATION MANAGEMENT SOLUTIONS
6.9.1 ENHANCED REGULATORY SUBMISSION PROCESS TO AUGMENT GROWTH
6.10 CLINICAL DATA INTEGRATION PLATFORMS
6.10.1 GROWING VOLUME OF CLINICAL DATA AND IMPROVED CLOUD TECHNOLOGY TO PROPEL MARKET
6.11 SAFETY SOLUTIONS
6.11.1 GROWING ADOPTION OF ECLINICAL SOFTWARE TO SUPPORT MARKET GROWTH
6.12 OTHER SOLUTIONS
7 ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL
7.1 INTRODUCTION
7.2 WEB-HOSTED & CLOUD-BASED MODELS
7.2.1 GROWING DEMAND FOR CLOUD-BASED SOLUTIONS TO AUGMENT GROWTH
7.3 ON-PREMISE MODELS
7.3.1 MINIMIZED DATA BREACHES AND EXTERNAL ATTACK RISKS TO SUPPORT MARKET
8 ECLINICAL SOLUTIONS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DATA COLLECTION
8.2.1 IMPROVED TRIAL EFFICIENCY TO DRIVE MARKET
8.3 DOCUMENT MANAGEMENT & STORAGE
8.3.1 RISING INCLINATION TOWARD STREAMLINED DOCUMENT WORKFLOWS TO FUEL MARKET
8.4 SUPPLY MANAGEMENT
8.4.1 NEED TO ADDRESS COMPLEXITIES IN MANAGING CLINICAL TRIAL SUPPLIES TO BOOST MARKET
8.5 DATA ANALYTICS
8.5.1 INCREASING NEED FOR OPTIMIZED TRIAL DESIGNS TO AID GROWTH
8.6 CLINICAL TRIAL OPERATIONS
8.6.1 GROWING FOCUS ON ENHANCED DRUG DEVELOPMENT TO PROPEL MARKET
8.7 REGULATORY INFORMATION MANAGEMENT
8.7.1 EVOLVING GLOBAL REGULATORY STANDARDS TO STIMULATE GROWTH
8.8 OTHER APPLICATIONS
9 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
9.1 INTRODUCTION
9.2 PHASE I
9.2.1 INCREASING DEMAND FOR ACCURATE CLINICAL DATA MANAGEMENT TO ACCELERATE GROWTH
9.3 PHASE II
9.3.1 PUSH TOWARD FASTER DRUG DEVELOPMENT TO FACILITATE GROWTH
9.4 PHASE III
9.4.1 INVOLVEMENT OF LARGE PATIENT POPULATION TO ENCOURAGE SEGMENT GROWTH
9.5 PHASE IV
9.5.1 GROWING EMPHASIS ON SAFE DRUGS TO DRIVE MARKET
10 ECLINICAL SOLUTIONS MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
10.2.1 INCREASING R&D EXPENDITURE TO DRIVE MARKET
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.3.1 GROWING OUTSOURCING OF CLINICAL TRIALS TO FUEL MARKET
10.4 CONSULTING SERVICE COMPANIES
10.4.1 INCREASING COMPLEXITIES AND COSTS OF CLINICAL DATA MANAGEMENT TO PROPEL MARKET
10.5 MEDICAL DEVICE MANUFACTURERS
10.5.1 RISING DEVELOPMENT OF NEW MEDICAL DEVICES TO BOOST MARKET
10.6 HOSPITALS & HEALTHCARE PROVIDERS
10.6.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND ECLINICAL SOLUTION PROVIDERS TO STIMULATE MARKET
10.7 ACADEMIC & RESEARCH INSTITUTES
10.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO EXPEDITE GROWTH
10.8 GOVERNMENT ORGANIZATIONS
10.8.1 INCREASED ADOPTION BY HEALTH DEPARTMENTS AND REGULATORY BODIES TO SPEED UP GROWTH
10.9 OTHER END USERS
11 ECLINICAL SOLUTIONS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Rising government funding for pharmaceutical R&D to drive market
11.2.3 CANADA
11.2.3.1 Advanced facilities and shorter approval times for drug candidates to fuel market
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 High number of sponsored clinical trials to augment growth
11.3.3 UK
11.3.3.1 Increased investments by pharmaceutical companies to boost market
11.3.4 FRANCE
11.3.4.1 Booming generics market to aid growth
11.3.5 ITALY
11.3.5.1 Favorable drug approval scenario to support market growth
11.3.6 SPAIN
11.3.6.1 Robust network of research centers, universities, and hospitals to encourage growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Low manufacturing costs and huge demand for medicines to expedite growth
11.4.3 INDIA
11.4.3.1 Growing foreign direct investments to facilitate market growth
11.4.4 JAPAN
11.4.4.1 Drug discovery and development initiatives to promote growth
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Higher adoption of advanced digital technologies to stimulate growth
11.5.3 MEXICO
11.5.3.1 Government initiatives to enhance digital infrastructure of healthcare to propel market
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2 GCC COUNTRIES
11.6.2.1 Growing modernization initiatives in healthcare sector to support market growth
11.6.3 REST OF MIDDLE EAST & AFRICA
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.3 REVENUE ANALYSIS, 2019–2023
12.4 MARKET SHARE ANALYSIS, 2023
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
12.5.5.2 Product footprint
12.5.5.3 Application footprint
12.5.5.4 End-user footprint
12.5.5.5 Region footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 COMPANY EVALUATION AND FINANCIAL METRICS
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES AND ENHANCEMENTS
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 MEDIDATA (A DASSAULT SYST?MES COMPANY)
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches and enhancements
13.1.1.3.2 Deals
13.1.1.4 MnM view
13.1.1.4.1 Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 VEEVA SYSTEMS
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Product launches and enhancements
13.1.2.3.2 Deals
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 IQVIA INC.
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Deals
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 ICON PLC
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Product launches and enhancements
13.1.4.3.2 Deals
13.1.5 ORACLE
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Deals
13.1.6 SIGNANT HEALTH
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Product launches and enhancements
13.1.6.3.2 Deals
13.1.7 CLARIO
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Product launches and enhancements
13.1.7.3.2 Deals
13.1.7.3.3 Other developments
13.1.8 ECLINICAL SOLUTIONS
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product launches and enhancements
13.1.8.3.2 Deals
13.1.9 CLINION
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.9.3 Recent developments
13.1.9.3.1 Product launches and enhancements
13.1.9.3.2 Deals
13.1.10 MAXISIT
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.11 4G CLINICAL
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.11.3 Recent developments
13.1.11.3.1 Deals
13.1.12 FOUNTAYN
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.13 SAAMA
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3.1 Deals
13.1.14 MEDNET
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.14.3 Recent developments
13.1.14.3.1 Product launches and enhancements
13.1.14.3.2 Deals
13.1.15 ADVARRA
13.1.15.1 Business overview
13.1.15.2 Products offered
13.1.15.3 Recent developments
13.1.15.3.1 Product launches and enhancements
13.1.15.3.2 Deals
13.1.16 CAIDYA
13.1.16.1 Business overview
13.1.16.2 Products offered
13.1.16.3 Recent developments
13.1.16.3.1 Deals
13.1.16.3.2 Expansions
13.1.17 OPENCLINICA, LLC
13.1.17.1 Business overview
13.1.17.2 Products offered
13.1.17.3 Recent developments
13.1.17.3.1 Deals
13.1.18 EVIDENTIQ
13.1.18.1 Business overview
13.1.18.2 Products offered
13.1.18.3 Recent developments
13.1.18.3.1 Product launches and enhancements
13.1.18.3.2 Deals
13.2 OTHER PLAYERS
13.2.1 RESEARCH MANAGER
13.2.2 ANJU SOFTWARE INC.
13.2.3 MEDRIO
13.2.4 CASTOR
13.2.5 REALTIME SOFTWARE SOLUTIONS, LLC
13.2.6 YPRIME, LLC.
13.2.7 VIAL
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
Over the years, endoscopy has evolved significantly and is widely used for the diagnosis and treatment of various disorders like cancer, GERD, and obesity, among others. In the past few years, the market has witnessed significant technological advancements, as companies have introduced new endoscopy and camera systems. This has aided in the diagnosis and treatment of diseases. This report covers the definition, description, and forecast of the global endoscopy market in terms of endoscopes, visualization systems, accessories, and by the applications for these instruments.
The global endoscopy market was valued at $xx billion in 2013 and is expected to reach $xx billion by 2018, at a CAGR of xx%. Growth in patient preference for minimally invasive surgeries and the presence of a favorable reimbursement environment in selected countries are the major factors driving the growth of this market. Moreover, various government bodies have extended their help in the form of investments, funds, and grants, which has stimulated the usage of advanced endoscopy systems.
Growth in the endoscopy market is driven by Asian countries like China, India, and Japan as well as countries like Australia, New Zealand, and UAE. The global endoscopy market is broadly segmented into four product categories, namely, endoscopes, visualization systems, other instruments, and accessories. In 2013, the endoscopes market accounted for the largest share—around xx%—of the global endoscopy market, by segment. This market was valued at $xx billion in 2013 and is expected to reach $xx billion by 2018, at a CAGR of xx% from 2013 to 2018. The visualization systems market closely followed the endoscopes market and is expected to grow at a CAGR of xx% to reach $xx billion by 2018 from $xx billion in 2013. The growth of this market is likely to be driven by the rising incidences of cancer and increasing preference for minimally invasive surgeries, particularly for capsule endoscopes.
Visualization systems form an integral part of an endoscopic instrument. The market for visualization systems is segmented into endoscopy cameras, video processors, video convertors, camera heads, light sources, wireless displays and monitors, transmitters and receivers, and others. The wireless displays and monitors segment held the largest share of the visualization systems market. This segment is also expected to grow at the highest CAGR of xx% from 2013 to 2018, to reach $xx billion by 2018.
The endoscopy market is dominated by Ethicon (Johnson & Johnson) (U.S.), Olympus Corporation (Japan), Covidien Pic (Ireland), Karl Storz GmbH (Germany), Boston Scientific, Inc. (U.S.), and Stryker Corporation (Japan). These players jointly accounted for -xx% of the overall market share. Cook Medical Incorporated (U.S.), Hoya Corporation (Pentax Medical System) (Japan), Fujifilm Holding Corporation (Fujinon) (Japan), Richard Wolf GmbH (Germany), Smith and Nephew, Inc. (U.S.), and Conmed Corporation (U.S.) are some of the other prominent players in the global endoscopy market.
